Results 131 to 140 of about 2,146 (159)

Ravulizumab

Reactions Weekly
  +6 more sources

Ravulizumab-related meningococcal sepsis post rituximab

Practical Neurology
Complement inhibition is a highly effective strategy for preventing relapse and disability accumulation in neuromyelitis optica spectrum disorder (NMOSD). Invasive infection with Neisseria meningitidis , the principal risk of complement inhibition, is largely mitigated by adequate vaccination.
Katharine Kline, Alexandra Raleigh, Heidi Beadnall, Judith M Spies, Elizabeth Thompson, Nicolas Urriola, Stephen Adelstein, Heinz Wiendl, Michael Barnett   +8 more
openaire   +2 more sources

Ravulizumab

Reactions Weekly, 2021
openaire   +1 more source

Eculizumab/ravulizumab

Reactions Weekly, 2023
openaire   +1 more source

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

British Journal of Haematology, 2020
Peter Hillmen, Robert Brodsky
exaly  

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

Patient Related Outcome Measures, 2023
Carlo Antozzi, Renato Mantegazza
exaly  

Mycophenolate-mofetil/ravulizumab/steroids

Reactions Weekly, 2023
openaire   +1 more source

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature

Frontiers in Immunology, 2023
Laura Daprai, Bruno Fattizzo, Wilma Barcellini   +2 more
exaly  

Ravulizumab in patients with generalised myasthenia gravis

Medicom Conference Report AAN 2022, 2022
Tuan Hoang Vu, Michiel Tent
openaire   +1 more source

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Kidney International, 2020
Garrouste Cyril, Spero Cataland, Maria Cappuccilli   +2 more
exaly